Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure News
Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure News Yahoo! Finance Canada
Covered in this story
What has happened since
- Abbott Laboratories is up 2.2% since this was published, 3 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Abbott Laboratories
- Rothschild & Co Redburn: $97.5 → $127 by Oct 2027 via Investing.com
- TD Cowen: $117 → $135 by Aug 2027 · Buy via Investing.com India
- UBS: $107 → $125 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 47 stories mentioning Abbott Laboratories, the earliest published 8 Jun 2026.
Summary aggregated from Yahoo! Finance Canada's public RSS feed. The full reporting belongs to Yahoo! Finance Canada — please read it on their site.